1-7 of 7
Heather A. Rasmussen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Circulating Tumor DNA in Untreated Classical Hodgkin Lymphoma Patients Treated with Pembrolizumab and Chemotherapy: Dynamic Response Assessment and Correlation with Baseline Metabolic Tumor Volume

Ryan C. Lynch, Stefan K. Alig, Chaitra S. Ujjani, Christina Poh, Edus H. Warren, Stephen D. Smith, Mazyar Shadman, Andrei Shustov, Brian G. Till, Vikram Raghunathan, Yolanda D. Tseng, Hilary Coye, Megan Shelby, Susan Ottemiller, Sarith Keo, Kaitlin Verni, Hongyan Du, Jacquelin Vandermeer, Ashley Gaston, Heather A. Rasmussen, Avanti Gulhane, Delphine Chen, Eric Wayne Dean, Paul S. Martin, Edmond A Marzbani, Jenna M. Voutsinas, Ash A. Alizadeh, Ajay K. Gopal
Journal: Blood
Blood (2022) 140 (Supplement 1): 6547–6549.
https://doi.org/10.1182/blood-2022-160234
Published: 2022
Journal Articles

Concurrent Pembrolizumab with AVD for Untreated Classical Hodgkin Lymphoma

Ryan C. Lynch, Chaitra S. Ujjani, Christina Poh, Edus H. Warren, Stephen D. Smith, Mazyar Shadman, Andrei R Shustov, Brian G. Till, Yolanda D. Tseng, Hilary Coye, Megan Shelby, Susan Ottemiller, Hongyan Du, Jacquelin Vandermeer, Heather A. Rasmussen, Stefan Alig, Ash A. Alizadeh, Avanti Gulhane, Delphine Chen, Eric Wayne Dean, Jason Lukas, Paul S. Martin, Edmond A Marzbani, Jenna Voutsinas, Ajay K Gopal
Journal: Blood
Blood (2021) 138 (Supplement 1): 233.
https://doi.org/10.1182/blood-2021-144610
Published: 2021
Journal Articles

Pembrolizumab with R-CHOP in Previously Untreated Diffuse Large B-Cell Lymphoma: Long Term Follow up and Analysis of the Mechanism of Pdl-1 Tumor Expression

Stephen D. Smith, MD, Jonathan R. Fromm, MD PhD, Min Fang, MD PhD, Brian G. Till, MD, Mazyar Shadman, MDMPH, Ryan C. Lynch, MD, Andrew J. Cowan, MD, Qian Vicky Wu, PhD, Jenna Voutsinas, MPH, Heather A. Rasmussen, BS, Katie Blue, Chaitra S. Ujjani, MD, Andrei R Shustov, MD, Ryan D. Cassaday, MD, Ajay K. Gopal, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 13–14.
https://doi.org/10.1182/blood-2020-137328
Published: 2020
Journal Articles

Dose-Dense Brentuximab Vedotin Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Is Highly Active for Second Line Treatment in Relapsed/Refractory Classical Hodgkin Lymphoma: Final Results of a Phase I/II Study

Ryan C. Lynch, MD, Ryan D. Cassaday, MD, Stephen D. Smith, MD, Jonathan R. Fromm, MD PhD, Andrew J. Cowan, MD, Edus H. Warren, MD PhD, Mazyar Shadman, MDMPH, Andrei R Shustov, MD, Brian G. Till, MD, Chaitra S. Ujjani, MD, Edward Libby, MD, Mary Philip, MDPhD, Hilary Coye, PA-C, Christen N. Martino, NP, Sandra Kanan, MSN, ARNP, Karolyn K. Morris, BA, Heather A. Rasmussen, BS, Sanaz Behnia, MD, Margaret E. Nartea, BS, Jenna M. Voutsinas, MPH, Ajay K. Gopal, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 16–18.
https://doi.org/10.1182/blood-2020-133763
Published: 2020
Journal Articles

Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Final Results from a Prospective Phase II Study

Solomon A. Graf, MD, Ryan D. Cassaday, MD, Karolyn K. Morris, BA, Sanaz Behnia, MD, Qian Vicky Wu, PhD, Jenna M. Voutsinas, MPH, Ryan C. Lynch, MD, Elizabeth Krakow, MD, Heather A. Rasmussen, BS, Thomas R. Chauncey, MD PhD, Sandra Kanan, MSN, ARNP, Lorinda A. Soma, MD, Stephen D. Smith, MD, Ajay K. Gopal, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1596.
https://doi.org/10.1182/blood-2019-126086
Published: 2019
Journal Articles

Ibrutinib Is Effective in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Results from a Prospective Phase II Study

Solomon A. Graf, MD, Ryan D. Cassaday, MD, Karolyn K. Morris, Heather A. Rasmussen, BS, Pamela S. Becker, MD, Thomas R. Chauncey, MD PhD, Sandra Kanan, MSN, ARNP, Lorinda A. Soma, MD, Stephen D. Smith, MD, Ajay K. Gopal, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2954.
https://doi.org/10.1182/blood-2018-99-115476
Published: 2018
Journal Articles

A Pilot Study of Weekly Brentuximab Vedotin in Patients with CD30+ Malignancies Resistant to Every 3 Week Brentuximab Vedotin

Jacqueline N. Poston, MD, Jonathan R. Fromm, MD PhD, Heather A. Rasmussen, BS, Andrei R. Shustov, MD, Edward N. Libby, III, MD, Stephen D. Smith, MD, Ted Gooley, PhD, Ajay K. Gopal, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1528.
https://doi.org/10.1182/blood.V130.Suppl_1.1528.1528
Published: 2017